Significantly more men than women saw an improvement in their disease activity a year after starting a biologic, but more research is needed to understand why.
The American College of Rheumatology’s 2020 medical conference had a number of important updates that people living with axial spondyloarthritis (or their caregivers) should know about, from the role of “treat to target” to gender differences in symptoms.
Many axial spondyloarthritis patients are talking with their providers about their treatment plan — and wanting to prevent long-term damage is a major factor in how they think about it.
Some people may experience AS mild symptoms and not much progression; others can have more serious symptoms that continue to get worse.
With its own diagnostic code, non-radiographic axial spondyloarthritis may become easier to diagnose and study over time.
Many people do not suspect arthritis as a cause of their back pain, even though arthritis in the back is very common.
While many studies have shown these medications help treat AS symptoms, more research has been needed about their impact on long-term disease progression.
‘I’ve got no idea how to use pain scales to record different kinds of pain … from different sources … and at different times and intensities.’
‘Identification, evaluation, and management of enthesitis is critical to ameliorate the overall burden of disease,’ according to researchers.
“An improved risk stratification and vigilance for early diagnosis and treatment of AS particularly in African American patients is needed,” say study authors.